PTLA Portola Pharmaceuticals, Inc.

25.14
+0.19  (0.76%)
Previous Close 24.95
Open 25.17
Price To book 5.96
Market Cap 1.42B
Shares 56,543,000
Volume 1,671,914
Short Ratio 8.76
Av. Daily Volume 1,054,910

SEC filingsSee all SEC filings

  1. 8-K - Current report 162066637
  2. 8-K - Current report 162054447
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161979208
  4. 8-K - Current report 161978176
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161880404

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 24, 2017. Phase 3 data released March 2016 did not meet primary endpoint.
Betrixaban (The APEX Study)
Venous thromboembolism (VTE) Prevention
Phase 2 enrolment commenced May 2016. Continues to enroll as of November 2016.
Cerdulatinib (PRT2070)
Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer
CRL August 17 2016
Andexanet alfa
Factor Xa inhibitor reversal agent

Latest News

  1. Why Portola Pharmaceuticals Crashed 56.4% In 2016
  2. 3 Little-Known Pharmaceutical Companies to Put on Your Radar
  3. 2 Top Stocks in Biotech
  4. My Worst Predictions for Biotech in 2016
  5. Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
  6. Portola Pharmaceuticals to Webcast Corporate Update on January 10, 2017
  7. Portola Pharma upgraded by Citigroup
  8. Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
  9. Why Portola Pharmaceuticals Inc Stock Surged Higher Today
  10. Why Portola Pharmaceuticals, Caesars Entertainment, and Cal-Maine Foods Jumped Today
  11. Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
  12. Portola Pharmaceuticals Announces FDA Accepts New Drug Application for Priority Review and EMA Validates Marketing Authorization Application for Oral, Factor Xa Inhibitor Anticoagulant Betrixaban
  13. PORTOLA PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an O
  14. Portola Pharmaceuticals, Inc. – Value Analysis (NASDAQ:PTLA) : December 21, 2016
  15. Bristol-Myers Squibb Co (BMY) And Pfizer Inc. (PFE) Agree To $50 Million Loan To Portola Pharmaceuticals Inc (PTLA)
  16. Portola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : December 20, 2016
  17. Portola Pharma Wins on Pfizer and Bristol-Myers Loan Agreement
  18. Portola Pharmaceuticals Enters into $50 Million Loan Agreement with Bristol-Myers Squibb and Pfizer for Continued Development of AndexXa™ (andexanet alfa)

SEC Filings

  1. 8-K - Current report 162066637
  2. 8-K - Current report 162054447
  3. 10-Q - Quarterly report [Sections 13 or 15(d)] 161979208
  4. 8-K - Current report 161978176
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 161880404
  6. 8-K - Current report 161843843
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161818512
  8. 8-K - Current report 161818312
  9. 8-K - Current report 161726780
  10. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 161711962